This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
![Cover of StatPearls](/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-statpearls-lrg.png)
StatPearls [Internet].
Show detailsIntroduction
Calcium is a prominent molecule in the body involved in many biochemical processes. This mineral is essential for proper cardiac function, the structural integrity of bone, muscular contraction, and acts as an enzymatic signal in biochemical pathways.[1] Calcium is tightly regulated by the parathyroid hormone (PTH), calcitonin, and calcitriol, which regulate serum calcium levels. Calcium must be ingested endogenously, and absorption in the gastrointestinal system is influenced by hormones PTH and calcitriol (1,25-dihydroxyvitamin D).[2]
Serum calcium can be measured by a venous sample, with physiologic levels ranging from 8.8 mg/dL to 10.4 mg/dL for total calcium and 4.7 mg/dL to 5.2 mg/dL for ionized calcium.[3] Total calcium values should be corrected for current albumin concentrations, which act as a carrier protein and can affect the reported results. Calcium can also be analyzed from urine by calcium concentration, urine calcium to creatinine ratio (UCa: UCr), or fractional excretion of calcium (FeCa). Calcium derangements can result from many diseases or therapies that affect hormone secretion, receptor sensitivities, intestinal absorption, and renal effectiveness.[4] Laboratory error can cause inaccurately reported calcium levels, and preventive measures should be included in specimen collection and analysis.
Etiology and Epidemiology
Calcium is the fifth most common element in the body and the most prevalent cation. An average human body (70 kg) contains about 1 kg, or approximately 25 mol, of calcium.[5] The skeleton contains approximately 99% of the body’s calcium, predominantly as extracellular crystals of an unknown structure and a composition approaching hydroxyapatite.[4] Soft tissues and extracellular fluid contain about 1% of the body’s calcium. In blood, virtually all calcium is present in the plasma.[5]
About 50% of the calcium present in circulation is free (also known as ionized calcium); 40% of serum calcium is bound to proteins, especially albumin (80%) and, secondary, to globulins (20%); and about 10% exists as various small diffusible inorganic and organic anions (eg, bicarbonate, lactate, citrate). The free calcium fraction is biologically active.[6] Because calcium binds to negatively charged sites on proteins, its binding is pH-dependent. Alkalosis leads to an increase in the negative charge of proteins, increasing binding and decreasing free calcium; conversely, acidosis leads to a decrease in negative charge, decreasing binding and increasing free calcium.[7] In vitro, for each 0.1-unit change in pH, approximately 0.2 mg/dL (0.05 mmol/L) of inverse change occurs in the serum-free calcium concentration.[8] Calcium can be redistributed among the 3 plasma pools, acutely or chronically, by alterations in the concentrations of protein and small anions, changes in pH, or changes in the quantities of free calcium and total calcium in the plasma.[9]
Calcium is physiologically classified as intracellular or extracellular. Intracellular calcium is key in many important physiologic functions, including muscle contraction, hormone secretion, glycogen metabolism, and cell division. The intracellular concentration of calcium in the cytosol of unstimulated cells is around 0.1 μmol/L, which is less than 1/20,000 of that in extracellular fluid.[10] Extracellular calcium provides calcium ions for maintaining intracellular calcium, bone mineralization, blood coagulation, and plasma membrane potential.[11] Calcium stabilizes the plasma membranes and influences permeability and excitability. A decrease in the plasma-free calcium concentration causes increased neuromuscular excitability and can lead to tetany; an increased concentration reduces neuromuscular excitability.[12]
Pathophysiology
Calcium is tightly regulated and rarely varies from physiologic levels within the body.[9] Homeostasis must be maintained as calcium is critical in many principal cellular functions.
The parathyroid hormone (PTH), calcitonin, and calcitriol actively manage calcium levels. The PTH is an essential regulator of calcium homeostasis, which acts on the renal, skeletal, and gastrointestinal systems to increase serum calcium levels. First, PTH promotes calcium absorption in the gut by stimulating the formation of renal-derived calcitriol (1,25-dihydroxyvitamin D), which targets the intestines to increase calcium absorption.[11][13] Second, PTH stimulates calcium resorption from bone by increasing osteoclast number and activity.[14] Lastly, PTH promotes calcium absorption in the kidney by activating adenylyl cyclase in the distal nephron.[15]
PTH is regulated by serum calcium via negative feedback, preventing excess PTH secretion when calcium is at the physiological level (10 mg/dL).[14] Calcium-sensing receptors (CaSRs) of the parathyroid gland (to control PTH secretion) continuously monitor calcium levels. Genetic mutations of CaSRs, such as those found in familial hypocalciuric hypercalcemia (FHH), can affect the sensitivity of the receptors to serum calcium levels, resulting in hypo- or hypercalcemia.[9] Calcitonin is secreted by the parafollicular C-cells of the thyroid gland in response to elevated serum calcium levels and acts to inhibit osteoclast activity and decrease calcium absorption in the intestines and kidneys.[16] The overall result is lower serum calcium levels.
Calcium and the Renal System
The PTH acts on the renal system by activating adenylyl cyclase and 1- alpha-hydroxylase to increase calcium reabsorption and phosphate excretion. Adenylyl cyclase increases calcium reabsorption at the distal convoluted tubules. The enzyme 1-alpha-hydroxylase increases the conversion of vitamin D to its active form, 1,25-dihydroxyvitamin D, resulting in increased calcium absorption in the intestine.[17] In chronic kidney disease, the effect of PTH can become muted, leading to hypocalcemia, hyperphosphatemia, and secondary hyperparathyroidism.[5]
Calcium and the Gastrointestinal System
Humans do not endogenously create calcium, so this mineral must be ingested and absorbed in the gastrointestinal tract. Calcium levels and 1,25-dihydroxyvitamin D (calcitriol) influence calcium absorption in the small intestine. Other factors such as age, gender, race, and comorbidities can affect calcium absorption. Calcitriol is increased in response to low serum calcium and triggers an active process in the duodenum to absorb more calcium.[13] Elevated serum calcium levels shut off the active process, and calcium absorption occurs passively at the jejunum and ileum, resulting in lower calcium absorption rates.[5] Since calcium is absorbed in ionic form, dietary intake of compounds that interact with calcium will reduce the amount of calcium available for absorption. These are primarily oxalate, phosphate, sulfate, citrate, fiber, and fats.[13]
Calcium and the Musculoskeletal System
Bone tissue stores calcium as hydroxyapatite, deposited when serum calcium levels are elevated and released when levels are low. This process is linked with the endocrine system via the thyroid and parathyroid glands. When serum calcium levels are elevated, the thyroid gland releases calcitonin, which inhibits bone resorption by halting osteoclast activity. The PTH effect on bone tissue is dependent on continuous versus intermittent exposure.[14] In continuous exposure, PTH activates osteoclasts more readily by enhancing RANKL, which increases calcium resorption and bone loss, promoting an osteoporotic state.[17] Intermittent PTH exposure favors osteoblast activation, which promotes bone formation. However, chronically reduced PTH levels precipitate decreased bone remodeling and, subsequently, weak and brittle bones.[18]
Calcium is necessary for muscle contraction. Actin and myosin subunits interact to initiate contraction, and two regulatory subunits, troponin and tropomyosin, actively inhibit this process. Tropomyosin obstructs the actin-myosin binding site, which prevents contraction by blocking actin and myosin interaction.[19] Muscle contraction occurs when calcium, released from the sarcoplasmic reticulum, binds troponin to force tropomyosin out of the binding site, thus allowing for actin and myosin interaction.[20]
Calcium and the Cardiovascular System
Calcium in the heart muscle cells stabilizes the membrane potential.[9] Calcium influx during the plateau phase of myocardial contractility sets the speed of pacemaker potential. Dysregulation of either calcium or potassium can affect this delicate balance. For example, if a patient presents with severe hyperkalemia, order an electrocardiogram to evaluate for abnormal changes, and administration of calcium gluconate is the initial step to stabilize the myocardium and prevent arrhythmias.[21]
Prospective cohort studies have shown no relationship between dietary calcium intake and the risk of heart disease, death, or myocardial infarction.[22] Study results conclude an unclear interpretation of whether absorption of dietary calcium versus calcium supplements has any indications regarding cardiovascular risks. Therefore, further investigations are recommended to discover the role of these supplements in cardiovascular prevention.[23]
Calcium is a key cofactor in the coagulation cascade and is necessary for appropriate coagulability. During primary hemostasis, von Willebrand Factor (vWF) is released from injured tissue to act as a bridge for the endothelium and platelet GpIb receptors for proper platelet adhesion. After a platelet adheres to the endothelium, calcium is released to assist with other coagulation factors of the clotting cascade.[24] The tissue factor released from subendothelial tissue binds to calcium and factor VII to promote thrombin formation. Calcium is also involved in forming the prothrombinase complex, which converts prothrombin to thrombin and further creates insoluble fibrin.[25] Results from a study of intracerebral hemorrhage among 2103 patients showed that hypocalcemia was associated with subtle coagulopathy and correlated with increased bleeding in patients with intracerebral hemorrhage.[26]
Specimen Requirements and Procedure
Fasting is not a requirement to evaluate serum calcium levels. Calcium is included in the comprehensive metabolic panel (CMP), facilitating routine evaluation. Fist-clenching or forearm exercise can falsely elevate ionized (free) calcium levels. Draw the sample while the patient sits, as standing increases the total calcium concentration.[27] Hemolysis and delayed plasma/serum separation lead to a decreased calcium concentration. Samples collected in tubes containing citrate, oxalate, or ethylenediaminetetraacetic acid (EDTA) are unsuitable for calcium testing.[28]
A venous blood sample is required to evaluate serum levels. For children, a lancet needle can be used on a finger, and the sample can be collected in a pipette, slide, or test strip. Analyze whole blood specimens within 15 to 30 minutes of collection. If this is not possible, keep the specimen on ice. On the ice, the specimen is stable for at least 2 hours; however, if concurrent potassium testing is requested on the same specimen, the low temperature leads to a spurious increase in potassium within 1 hour of collection.[29] If the specimen cannot be analyzed within 1 hour, the preferred specimen is serum. Centrifuge the specimen and remove the serum or plasma from the cells within 2 hours of collection.[30]
Samples can be stored at room temperature for 8 hours or refrigerated at 2 °C to 8 °C for up to 48 hours. If assays are not completed within 48 hours, or if the separated sample needs to be stored beyond 48 hours, freeze samples at -15 °C to -20 °C. Only thaw frozen samples once. Analyte deterioration may occur in samples that are repeatedly frozen and thawed.[29]
Urine calcium can remain dissolved by adding 10 mL of 6 mol HCl to the collection container before a 24-hour specimen is collected. Urine should be well-mixed during the collection period. A 24-hour urine sample, timed collection, or random urine sample can help diagnose metabolic abnormalities and a patient’s disposition to form stones.[31] Urine calcium can be measured in 3 ways: urine calcium concentration, urine calcium to creatinine ratio (UCa:UCr), and fractional excretion of calcium (FeCa). Normal levels of UCa occur if UCr is less than 0.14, and elevated levels higher than 0.20 indicates hypercalciuria.[32] FeCa can also be used to identify abnormal calcium metabolism, but it also requires urine and serum labwork for determination.[33]
- FeCa = (Urine calcium x Serum creatinine) / (Serum calcium × Urine creatinine)
Testing Procedures
Total calcium can be measured using the ion-specific electrode (ISE) potentiometric method. The sample must be pre-acidified to release all bound and complexed calcium to a free form. However, total calcium is commonly measured with spectrophotometric methods, such as the o-cresolphthalein complexone method, Arsenazo III method, atomic absorption spectrometry, or, rarely, isotope dilution mass spectrometry (ID-MS).[34] Ionized calcium can be measured in whole blood using the ISE potentiometric method.[35]
The free calcium analyzer consists of a system of pumps under microprocessor control that transport calibration solutions, samples, and wash solutions through a measuring cell containing calcium ion-selective, reference, and pH electrodes. Sensitive potentiometers measure the voltage difference between the calcium or pH and reference electrodes for calibrating solutions or samples. A microprocessor calibrates the system and calculates calcium concentration and pH.[36] Most instruments simultaneously measure the actual free calcium and pH at 37 °C.[37]
Calcium ISEs contain a calcium-selective membrane that encloses an inner reference solution of calcium chloride, often containing saturated silver chloride (AgCl) and physiologic concentrations of sodium chloride and potassium chloride, and an internal reference electrode. The reference electrode, usually Ag/AgCl, is immersed in this inner reference solution. Modern calcium ISEs use liquid membranes containing the ion-selective calcium sensor dissolved in an organic liquid trapped in a polymeric matrix.[38] Because ISEs measure ion activity, they are affected by the ionic strength of a specimen. Free calcium analyzers (and the associated calibrators) are optimized for serum, plasma, or whole blood specimens. Because the ionic strength of these fluids is primarily a result of the concentrations of Na+ and Cl− ions, calibrators are usually prepared in buffer and sodium chloride with a final ionic strength of 160 mmol/kg.[36]
Although the range of Na+ and Cl+ concentrations usually observed in serum or plasma does not cause a clinically significant error in measuring free calcium, significant errors can occur with other specimens unless the matrices and the ionic strength of the calibrators and samples are matched closely. Modern electrodes have high selectivity for calcium over Na+, K+, Mg2+, H+, and Li+ ions.[39]
Interfering Factors
Reported calcium levels can be influenced by many factors, such as the patient’s age, comorbidities, lifestyle, gender, medical therapies, and conditions during specimen retrieval. For example, if the sample was poor quality due to it being lipemic or hemolyzed, then calcium levels can be inaccurate.[40] Exercise immediately prior to specimen retrieval has also been shown to increase calcium levels.[41]
Certain medications may precipitate inaccurate measurements of calcium levels. Perchlorate has been reported to cause discrepancies in ionized calcium measurements, leading to false diagnoses of hypo or hypercalcemia.[42] Medications known to increase serum calcium levels are thiazide diuretics, lithium, antacids, and vitamin D supplements.[43]
Urine calcium excretion is highly related to sodium excretion; dietary sodium can influence reported levels. Diets high in sodium yield higher calcium excretion; similarly, low-sodium diets equal lower calcium excretion.[44] The clinician should remember children have an increased calcium-to-creatinine ratio and might be falsely determined to be hypercalciuric if they follow adult guidelines.[45]
Albumin is a carrier protein for calcium and can result in an inaccurately reported serum calcium level. Evaluating albumin levels to correct for total calcium and differentiate actual versus factitious calcium dysregulation is important.[46] The equation is as follows:
Albumin Correction
- True Calcium (mg/dL) = reported total calcium (mg/dL) + 0.8 (4.0 – serum albumin (g/dL))
If the corrected serum total calcium levels are between the normal levels of 8.8 mg/dL to 10.4 mg/dL, then the laboratory-reported calcium is fictitious due to impaired serum albumin levels.[47]
Results, Reporting, and Critical Findings
Hypercalcemia
Hypercalcemia occurs when calcium levels are above 10.4 mg/dL or if ionized serum calcium is above 5.2 mg/dL.[47] Patients with hypercalcemia may experience an array of symptoms, some of which include increased calcium stones, bone fragility/fractures, abdominal pain, constipation, thirst, frequent urination, and altered mentation in severe cases. Clinical findings have revealed tongue fasciculations, bradycardia, or hyperreflexia.[48] The first step after identifying hypercalcemia is to confirm by albumin correction. After confirming hypercalcemia, the next step is to measure the PTH level. If PTH is elevated, the patient’s hypercalcemia is PTH-dependent and can be caused by primary hyperparathyroidism, familial hypocalciuric hypercalcemia, or medication side effects. If PTH is suppressed, it is PTH-independent with a much broader differential, and lab values for parathyroid-related protein (PTHrP), 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D levels should be evaluated. The differential diagnosis for PTH-independent hypercalcemia includes immobilization, malignancy, medication-induced thyrotoxicosis, and vitamin D toxicity.[49]
Advise patients who are asymptomatic with albumin-corrected calcium levels less than 12 mg/dL to avoid precipitating factors such as dehydration, inactivity, a calcium diet greater than 1000 mg/day, and certain medications (lithium carbonate, thiazides).[50] Patients with albumin-corrected calcium levels greater than 12 mg/dL may present with mild, moderate, or severe symptoms.[51] Patients with chronic and mild symptoms of hypercalcemia may not require immediate treatment. However, patients with albumin-corrected calcium greater than 14 mg/dL require more urgent attention.[52]
Treatment with normal saline is the most beneficial early management of these patients. The addition of calcitonin should result in a significant reduction of serum calcium within 48 hours. Furthermore, administering bisphosphonates will provide a more sustained effect that will reduce calcium levels in 2 to 4 days.[52] Patients with renal failure or refractory to treatment with bisphosphonates can be managed with denosumab. Denosumab suppresses bone remodeling and may cause hypocalcemia; therefore, monitor patients for serum calcium and serum 25-hydroxyvitamin D.[53] As a last resort to treating severe hypercalcemia, hemodialysis is indicated for patients with malignancy-associated hypercalcemia and renal insufficiency.[54] Careful monitoring is required to avoid fluid overload, especially among patients with compromised cardiac reserve and renal insufficiency.[55]
Hypocalcemia
Hypocalcemia is total serum calcium levels below 8.8 mg/dL or ionized serum calcium below 4.7 mg/dL.[56] Due to multiple causal factors, patients with hypocalcemia must be carefully assessed based on laboratory values, clinical presentation, symptoms, medications, and comorbidities. The first step in diagnosing hypocalcemia is to confirm by albumin correction. One of the first signs of hypocalcemia is neuromuscular irritability, which presents symptoms such as tingling and numbness around the mouth and at the fingertips, paresthesia of the extremities, and painful muscle cramps.[57]
The physical exam could likely demonstrate contraction of facial muscles ipsilaterally by tapping on the skin overlying the facial nerve (Chvostek sign) and painful carpal spasms with wrist flexion and interphalangeal joint extension while the blood pressure cuff is set 20 mm Hg above the patient’s systolic pressure (Trousseau signs).[58] Acute versus chronic hypocalcemia can present differently. Acute hypocalcemia is more likely to present with cardiac dysfunctions such as QT-prolongation and T-wave abnormalities. Chronic hypocalcemia can present with skin manifestations, including dry skin, coarse hair, brittle nails, and neurologic problems, such as calcification of brain parenchyma.[59]
Hypocalcemia can occur due to diseases, treatments, medications, and electrolyte abnormalities. Metabolic alkalosis can cause decreased serum ionized calcium due to calcium-binding albumin more readily during alkalotic states. Chronic diseases of note are hypoparathyroidism, chronic kidney disease, liver disease, and vitamin D deficiency.[60] Acute illnesses such as sepsis, pancreatitis (due to fat saponification), and acute kidney injury can also result in hypocalcemia. Severe hypomagnesemia can secondarily cause hypocalcemia, as is sometimes seen in proton pump inhibitor (PPI) therapy. PPI therapy also decreases stomach acidity, decreasing calcium absorption via the intestinal tract. A case report in 2017 discussed 2 children on dialysis for chronic kidney disease (CKD) who experienced acute hypocalcemia and alkalotic episodes a week after starting sodium polystyrene sulfonate (SPS) for the treatment of hyperkalemia.[61]
Other medications of note that can result in hypocalcemia are the long-term use of corticosteroids, antiepileptics, aminoglycosides, cisplatin, and bisphosphonates.[56] Acute hypocalcemia is common among patients receiving large transfusions, such as during treatment of traumatic hemorrhage, due to citrate and chelation products. As calcium is vital for proper coagulation, closely monitor patients with trauma receiving blood transfusions to avoid severe hypocalcemic events.[62]
Treatment for hypocalcemia depends on the severity of the symptoms. Patients experiencing mild symptoms should be treated with calcitriol 0.5 mcg orally twice daily and calcium in the combined form of calcium carbonate with the dose of 500 mg orally 4 times daily to achieve optimal absorption. There are several ways to administer calcium. Calcium carbonate can be taken orally via pill or crushed and mixed with liquid. The absorption of calcium carbonate is dependent on stomach acidity. For better absorption, this may be taken with food or substituted with calcium citrate to stimulate an acidic environment.[63] If serum calcium levels are persistently low, possible hypomagnesemia must be evaluated and corrected to normalize serum calcium levels.[56]
On the other hand, calcium gluconate is available in liquid form. In severely symptomatic patients with hypocalcemia, it is essential to maintain a calcium level above 8 mg/dL (2 mmol/L). Hence, calcium gluconate can be administered by continuous intravenous drip infused over 10 to 20 minutes to avoid cardiac complications such as arrhythmias.[64] Evaluate serum calcium every 3 to 6 months and evaluate 24-hour urine calcium annually. Provide phosphate binders to avoid calcium phosphate precipitation and soft-tissue calcification if the patient has comorbid hyperphosphatemia.[60]
Hypocalciuria
Hypocalciuria can occur due to medications, diseases, and genetic disorders. Common medications that result in reduced urine calcium are thiazides and estrogen. Genetic conditions such as familial hypocalciuric hypercalcemia (FHH), an autosomal dominant disease that decreases the sensitivity of calcium-sensing receptors (CaSRs) of the parathyroid gland, maintain serum calcium levels at an elevated baseline with resulting hypocalciuria.[65] Another possible genetic cause is Gitelman syndrome, a salt-wasting tubulopathy that presents with spasms, muscle weakness, and salt cravings with multiple electrolyte derangements, including hypocalciuria.[66] Differential diagnosis also includes hypoparathyroidism, pseudohypoparathyroidism, intestinal malabsorption, rickets, and hypothyroidism.[67]
Hypercalciuria
Hypercalciuria can occur as an effect of medications, diseases, and genetic disorders. Spironolactone, corticosteroids, and acetazolamide are common medications involved.[68] Consider supplements containing extra calcium. Differential diagnosis includes hyperparathyroidism, malignancy, multiple myeloma, sarcoidosis, Paget disease, increased intestinal absorption, and osteoporosis.[69]
Clinical Significance
Calcium dysregulation can be a sign of many diseases, just as much as dysregulation can cause many adverse effects. This section will highlight various areas throughout the body in which calcium is related to pathologies.
Bone Health and Osteoporosis
Osteoporosis is a disorder that influences bone composition, affecting density and mineralization. The consequences can be dire as gradual bone loss can result in bone fragility and, ultimately, bone fracture. There are an estimated 1.5 million fractures each year due to osteoporosis, as this disorder affects more than 10 million US adults, the vast majority of whom are women.[70] However, men affected with osteoporosis are often unidentified and undertreated, with higher mortality rates due to hip fractures. Consumption of dietary calcium and vitamin D from childhood to early adulthood helps patients reach peak bone mass and delay severe bone loss during aging. For osteoporosis prevention, The American College of Obstetricians and Gynecologists (ACOG) has released recommendations for calcium and vitamin D supplementation for women starting as early as 9 years old, with dosage varying according to age.[71] Furthermore, calcium supplements reduce the risk of fractures and falls in adults aged 65 years and older.[72]
The United States Food and Drug Administration (FDA) association has approved a health claim suggesting that sufficient calcium and vitamin D intake, with consistent physical activity, might reduce the risk of osteoporosis later in life.[73] Contrasting to this view, in 2018 the U.S. Preventive Services Task Force (USPSTF) maintained there is insufficient evidence to suggest that supplementation with calcium and vitamin D has greater benefits than potential harm. Thus, the 2018 USPSTF guidelines recommend against supplementation of vitamin D and calcium to prevent fractures among “community-dwelling, asymptomatic adults.” This recommendation does not apply to symptomatic patients with osteoporosis or vitamin D deficiency history.
Gastrointestinal Malignancy
Calcium binds to bile acids and fatty acids to form insoluble complexes that protect the cell lining of the gastrointestinal tract from acids and their metabolites. Also, calcium is involved in improving signaling within the cells, which may reduce cell proliferation by promoting cells to undergo differentiation and or apoptosis.[74] Although studies are inconsistent, conclusions from data collection suggest that calcium may play a role in preventing colorectal cancer. The association between daily calcium intake and prevention of colorectal cancer showed an inverse association most strongly among older women and the distal colon.[75] However, more trials are needed to further conclude different studies on this topic. Currently, there is no FDA indication for calcium and cancer of the colon and rectum, as further studies are under current investigation.
Hypoparathyroidism
Low levels of PTH occur due to autoimmune or surgical destruction, abnormal congenital development, impaired PTH regulation, or muted PTH effect. The systemic effect is hypocalcemia, ranging from mild to severe symptoms.
Surgical destruction most often occurs during thyroid, parathyroid, or neck surgery. For example, this is the most common complication following a thyroidectomy, in which patients experience acute symptoms of seizures, laryngospasm, prolonged QT, or tetany.[76] Postsurgical symptoms can be transient due to glandular stress or partial parathyroid excision or permanent due to accidental excision.[77][78] Thus, patients should start taking calcium and vitamin D supplements after thyroid surgery and then taper slowly for 3 to 6 weeks to avoid symptoms of hypocalcemia.[76]
Autoimmune destruction is another acquired cause and typically begins during childhood or adolescence. The destruction that happens in permanent hypoparathyroidism is a part of autoimmune polyglandular syndrome type 1 (APS 1) due to mutations of the autoimmune regulator (AIRE) gene.[79] Further, activating CaSR antibodies can develop, causing fictitious negative feedback and decreased PTH secretion.[80]
Abnormal parathyroid development in utero can be a cause of hypoparathyroidism identified in infants and children. An example is DiGeorge syndrome due to a 22q11 deletion resulting in defective pharyngeal pouch development and its derivatives. The effects are cardiac anomalies, hypocalcemia, hypoplastic thymus, and immunodeficiency.[81]
Peripartum Effects
Professional organizations such the ACOG recommend 1500 mg to 2000 mg of calcium to prevent the risk of preeclampsia in pregnant women with a baseline calcium intake of 600 mg or less. Similarly, the World Health Organization (WHO) also recommends the same dosage of 1,500 mg to 2,000 mg for pregnant women with low dietary calcium intake and a high risk of gestational hypertension.[82] Results from a 2020 study with mouse models revealed that placental efficiency was improved among mice receiving adequate amounts of vitamin D and further showed that deficiencies resulted in altered placental morphogenesis and microstructure.[83] Calcitonin can increase during pregnancy and among lactating mothers--and is thought to be a protective measure to suppress maternal bone loss.[16]
Neonatal hypocalcemia can occur within the first few days of life. Prematurity is the most common factor predisposing a neonate to develop neonatal hypocalcemia. Other conditions that increase the risk include maternal diabetes, maternal hyperparathyroidism, and being small for gestational age.[84] Early-onset neonatal hypocalcemia is often asymptomatic and occurs within the first few days of life. Neonates at high risk for hypocalcemia should be monitored for the first 72 hours for possible hypocalcemia. Late-onset, which occurs after 72 hours, is generally symptomatic, and the neonate may show tachycardia, tachypnea, episodes of apnea, and seizures.[85]
Chronic Kidney Disease
During chronic kidney disease, the effect of PTH can be decreased due to poor renal response. As such, hypocalcemia, hyperphosphatemia, and secondary hyperparathyroidism can occur.[17] Due to elevated serum phosphate levels, the parathyroid glands will be activated to secrete more PTH, and the diseased kidney will remain unresponsive. Calcium-containing phosphate binders may be used to lower phosphate levels. Calciphylaxis is a rare complication from calcium-phosphate complexes due to rapid calcification of subcutaneous tissues causing necrotic skin ulcers, most commonly occurring during advanced renal failure.[86] Calcium citrate should be avoided in such patients due to increased intestinal aluminum absorption leading to neurotoxicity and the onset of osteomalacia.[87]
Clinicians should consider the potential consequences of oral calcium intake among patients with chronic kidney disease. Increased oral calcium intake is associated with an increased risk of vascular calcification, especially among patients on dialysis receiving calcium-containing phosphate binders versus non-calcium-containing phosphate binders. According to research analyses, treatment with calcium phosphate binders increased the progression of coronary and aortic calcification in patients with chronic kidney disease concomitantly undergoing hemodialysis.[88]
Conversely, the Dallas Heart Study examined the association between coronary artery calcification (CAC) in adults with end-stage kidney disease in the presence of diabetes. The study concluded that adults with comorbid diabetes and chronic kidney disease had an increased risk of coronary artery calcification as opposed to patients with chronic kidney disease alone.[89]
Calcium Nephrolithiasis
Increased calcium excretion contributes to the development of renal stones, comprised of either calcium oxalate or calcium phosphate.[13] In the past, patients were counseled to decrease their calcium intake to prevent hypercalciuria. However, according to research study results, dietary calcium intake decreases the risk of kidney stone formation [13] and is believed to be related to oxalate absorption through the intestinal tract. When calcium is ingested, a complex with oxalate can form, limiting both molecules’ intestinal absorption. However, with dietary calcium restriction, oxalate is more freely absorbed through the intestinal tract and subsequently excreted in greater quantity by the kidneys. As more oxalate is present in the renal system, there is increased calcium-oxalate complex formation, leading to kidney stones. A 2012 study evaluated this effect among 5400 women, and showed that women with a history of kidney stones had higher levels of calcium absorption and similarly found that increasing calcium intake resulted in lower absorption levels.[13] Thiazide diuretics increase renal calcium reabsorption, remove calcium from the renal system, and can be prescribed for calcium stone prevention in the absence of primary hyperthyroidism.[90]
Quality Control and Lab Safety
Laboratory errors during retrieval and analysis can provide inaccurate information to the medical team. Errors in calcium measurements have been reported when anticoagulant-containing collecting tubes are inadequately filled.[91] The method and quality of the sample can also affect calcium levels, especially among lipemic or hemolyzed samples, due to hemoglobin interference. Lipemia should be removed from the specimen before testing, as this is a source of many laboratory errors. A 2018 study analyzed methods used to recover lipemic samples and promote removal by ultracentrifugation as the best method to maintain specimen integrity without exceeding the limit for clinically significant interference.[92] Also reported is that venous occlusion during retrieval can mildly elevate calcium levels at the site due to hemodynamic changes. Suspicion of a lab error requires that a new sample be retrieved and evaluated.[5]
The Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations require laboratories to have quality control (QC) procedures to monitor the accuracy and precision of the complete testing process. For non-waived tests, the CLIA regulations require analyzing at least 2 levels of quality control materials once every 24 hours.[93] Laboratories can assay QC samples more frequently, if necessary, to ensure accurate results. It is important to assay QC samples after an analyzer has been calibrated or maintained to confirm the method’s precise performance.[94]
The acceptable range and guidelines for interpreting QC outcomes are important to ensure laboratory testing is accurate and reliable. The likelihood of identifying a noteworthy analytical error while keeping the false alert rate at an acceptable level is the basis for determining the acceptable range and guidelines for interpreting QC outcomes. Before choosing the appropriate QC rules, define the preferred performance characteristics for each measurement.[95] Typically, Westgard multi-rules are employed to assess the quality control runs. These rules are used to detect systematic errors, random errors, and shifts in the mean or standard deviation of the QC data. In the event of a declared out-of-control run, thoroughly investigate the system to pinpoint the underlying issue. Do not analyze until the problem has been rectified.[96]
The laboratory must participate in the external QC or proficiency testing program. Ensuring the accuracy and reliability of the laboratory compared to other laboratories performing the same or comparable assays is also helpful. Integrate the proficiency testing plan into the laboratory quality assurance (QA) plan and the overall quality program.[97]
Maintaining safety in clinical laboratories is a fundamental aspect of healthcare, ensuring the well-being of healthcare providers and patients; this involves a set of procedures and precautions to handle potentially harmful substances and biological materials with the highest level of caution. Safety encompasses correctly utilizing personal protective gear such as gloves, lab coats, and eyewear. Other safety protocols include handling specimens carefully to prevent contamination and uphold precision in diagnostic testing. Thorough decontamination procedures and appropriate waste disposal are also critical in averting the spread of infections. Moreover, regular training and educational initiatives provide lab personnel with the expertise to respond to emergencies and incidents effectively.[98] By adhering to these measures, clinical laboratories play a pivotal role in furnishing precise, dependable, and secure diagnostic services, significantly contributing to the quality of patient care.
Enhancing Healthcare Team Outcomes
Manage patient care appropriately to provide the best treatment to improve outcomes and reduce morbidity. Calcium is implicated in various biochemical pathways; therefore, understanding how this mineral can be affected by various diseases and medical therapies is essential. An interprofessional approach is recommended to tailor each patient’s needs and treatment. For example, patients taking bisphosphonates should receive continuous follow-ups for the adverse effects of long-term use, such as osteonecrosis of the jaw, particularly in patients with multiple myeloma or metastatic bone disease.[99] Many medical therapies and interventions can affect calcium homeostasis, necessitating medical teams to coordinate and communicate to discuss recommendations and assure patient safety.[100] Interprofessional patient care involving clinicians, nursing staff, pharmacists, and possibly dieticians can address calcium levels and coordinate activity to provide corrective actions when necessary, leading to optimal patient outcomes.
References
- 1.
- Cormick G, Belizán JM. Calcium Intake and Health. Nutrients. 2019 Jul 15;11(7) [PMC free article: PMC6683260] [PubMed: 31311164]
- 2.
- Gennari C. Calcium and vitamin D nutrition and bone disease of the elderly. Public Health Nutr. 2001 Apr;4(2B):547-59. [PubMed: 11683549]
- 3.
- Baird GS. Ionized calcium. Clin Chim Acta. 2011 Apr 11;412(9-10):696-701. [PubMed: 21238441]
- 4.
- Reid IR, Bolland MJ. Controversies in medicine: the role of calcium and vitamin D supplements in adults. Med J Aust. 2019 Nov;211(10):468-473. [PubMed: 31680267]
- 5.
- Schöfl C. [Update - Calcium Metabolism]. Dtsch Med Wochenschr. 2019 Aug;144(16):1125-1132. [PubMed: 31416104]
- 6.
- Nordin BE. Calcium and osteoporosis. Nutrition. 1997 Jul-Aug;13(7-8):664-86. [PubMed: 9263260]
- 7.
- Wilson RF, Binkley LE, Sabo FM, Wilson JA, Munkarah MM, Dulchavsky SA, Diebel LN. Electrolyte and acid-base changes with massive blood transfusions. Am Surg. 1992 Sep;58(9):535-44; discussion 544-5. [PubMed: 1524320]
- 8.
- Maier JD, Levine SN. Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy. J Intensive Care Med. 2015 Jul;30(5):235-52. [PubMed: 24130250]
- 9.
- Zheng J, Zeng X, Wang S. Calcium ion as cellular messenger. Sci China Life Sci. 2015 Jan;58(1):1-5. [PubMed: 25576449]
- 10.
- Canario A, Flik G. Endocrinology of calcium homeostasis. Gen Comp Endocrinol. 2007 Jun-Jul;152(2-3):242. [PubMed: 17586159]
- 11.
- Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev. 2005 Jan;85(1):373-422. [PubMed: 15618484]
- 12.
- Parekh AB, Putney JW. Store-operated calcium channels. Physiol Rev. 2005 Apr;85(2):757-810. [PubMed: 15788710]
- 13.
- Sorensen MD. Calcium intake and urinary stone disease. Transl Androl Urol. 2014 Sep;3(3):235-40. [PMC free article: PMC4708574] [PubMed: 26816771]
- 14.
- Talmage RV, Mobley HT. Calcium homeostasis: reassessment of the actions of parathyroid hormone. Gen Comp Endocrinol. 2008 Mar 01;156(1):1-8. [PubMed: 18160068]
- 15.
- Greger R, Lang F, Oberleithner H. Distal site of calcium reabsorption in the rat nephron. Pflugers Arch. 1978 May 18;374(2):153-7. [PubMed: 566424]
- 16.
- Felsenfeld AJ, Levine BS. Calcitonin, the forgotten hormone: does it deserve to be forgotten? Clin Kidney J. 2015 Apr;8(2):180-7. [PMC free article: PMC4370311] [PubMed: 25815174]
- 17.
- Duque EJ, Elias RM, Moysés RMA. Parathyroid Hormone: A Uremic Toxin. Toxins (Basel). 2020 Mar 17;12(3) [PMC free article: PMC7150960] [PubMed: 32192220]
- 18.
- Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. Can Fam Physician. 2012 Feb;58(2):158-62. [PMC free article: PMC3279267] [PubMed: 22439169]
- 19.
- Szent-Györgyi AG. Calcium regulation of muscle contraction. Biophys J. 1975 Jul;15(7):707-23. [PMC free article: PMC1334730] [PubMed: 806311]
- 20.
- Jiang H, Stephens NL. Calcium and smooth muscle contraction. Mol Cell Biochem. 1994 Jun 15;135(1):1-9. [PubMed: 7816050]
- 21.
- Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. Arch Dis Child. 2012 Apr;97(4):376-80. [PubMed: 21920871]
- 22.
- Xiao Q, Murphy RA, Houston DK, Harris TB, Chow WH, Park Y. Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health study. JAMA Intern Med. 2013 Apr 22;173(8):639-46. [PMC free article: PMC3756477] [PubMed: 23381719]
- 23.
- Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med. 2010 Mar 02;152(5):315-23. [PubMed: 20194238]
- 24.
- Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014 Sep;58(5):515-23. [PMC free article: PMC4260295] [PubMed: 25535411]
- 25.
- Yu J, Su H, Wei S, Chen F, Liu C. Calcium content mediated hemostasis of calcium-modified oxidized microporous starch. J Biomater Sci Polym Ed. 2018 Oct;29(14):1716-1728. [PubMed: 29813002]
- 26.
- Morotti A, Charidimou A, Phuah CL, Jessel MJ, Schwab K, Ayres AM, Romero JM, Viswanathan A, Gurol ME, Greenberg SM, Anderson CD, Rosand J, Goldstein JN. Association Between Serum Calcium Level and Extent of Bleeding in Patients With Intracerebral Hemorrhage. JAMA Neurol. 2016 Nov 01;73(11):1285-1290. [PMC free article: PMC5287716] [PubMed: 27598746]
- 27.
- Krahn J, Lou H. Ionized calcium: whole blood, plasma or serum? Clin Lab. 2008;54(5-6):185-9. [PubMed: 18780665]
- 28.
- Cao L, Chen M, Phipps RA, Del Guidice RE, Handy BC, Wagar EA, Meng QH. Causes and impact of specimen rejection in a clinical chemistry laboratory. Clin Chim Acta. 2016 Jul 01;458:154-8. [PubMed: 27166198]
- 29.
- Atay A, Demir L, Cuhadar S, Saglam G, Unal H, Aksun S, Arslan B, Ozkan A, Sutcu R. Clinical biochemistry laboratory rejection rates due to various types of preanalytical errors. Biochem Med (Zagreb). 2014;24(3):376-82. [PMC free article: PMC4210258] [PubMed: 25351356]
- 30.
- Jacobsz LA, Zemlin AE, Roos MJ, Erasmus RT. Chemistry and haematology sample rejection and clinical impact in a tertiary laboratory in Cape Town. Clin Chem Lab Med. 2011 Oct 14;49(12):2047-50. [PubMed: 21995606]
- 31.
- Jones AN, Shafer MM, Keuler NS, Crone EM, Hansen KE. Fasting and postprandial spot urine calcium-to-creatinine ratios do not detect hypercalciuria. Osteoporos Int. 2012 Feb;23(2):553-62. [PMC free article: PMC3295234] [PubMed: 21347742]
- 32.
- Rath B, Aggarwal MK, Mishra TK, Talukdar B, Murthy NS, Kabi BC. Urinary calcium creatinine ratio and hypercalciuria. Indian Pediatr. 1994 Mar;31(3):311-6. [PubMed: 7896367]
- 33.
- Felsenfeld AJ, Levine BS, Rodriguez M. Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease. Semin Dial. 2015 Nov-Dec;28(6):564-77. [PubMed: 26303319]
- 34.
- Ohnishi ST. A method of estimating the amount of calcium bound to the metallochromic indicator arsenazo III. Biochim Biophys Acta. 1979 Aug 22;586(2):217-30. [PubMed: 38853]
- 35.
- Copeland BE, Grisley DW, Casella J, Bailey H. Comparison of serum calcium measurements with respect to five models of atomic absorption spectrometers using NBS-AACC calcium reference method and isotope-dilution mass spectrometry as the definitive method. Am J Clin Pathol. 1976 Oct;66(4):619-33. [PubMed: 788497]
- 36.
- Sena SF, Bowers GN. Measurement of ionized calcium in biological fluids: ion-selective electrode method. Methods Enzymol. 1988;158:320-34. [PubMed: 3374382]
- 37.
- Huang WT, Shahid S, Anderson P. Validation of a Real-Time ISE Methodology to Quantify the Influence of Inhibitors of Demineralization Kinetics in vitro Using a Hydroxyapatite Model System. Caries Res. 2018;52(6):598-603. [PubMed: 29804111]
- 38.
- Carey CM, Vogel GL. Measurement of Calcium Activity in Oral Fluids by Ion Selective Electrode: Method Evaluation and Simplified Calculation of Ion Activity Products. J Res Natl Inst Stand Technol. 2000 Mar-Apr;105(2):267-73. [PMC free article: PMC4872681] [PubMed: 27551609]
- 39.
- Kaufman RA, Tietz NW. Ion effects in measurement of ionized calcium with a calcium-selective electrode. Clin Chem. 1980 Apr;26(5):640-4. [PubMed: 6266696]
- 40.
- West J, Atherton J, Costelloe SJ, Pourmahram G, Stretton A, Cornes M. Preanalytical errors in medical laboratories: a review of the available methodologies of data collection and analysis. Ann Clin Biochem. 2017 Jan;54(1):14-19. [PubMed: 27614351]
- 41.
- Lippi G, Banfi G, Church S, Cornes M, De Carli G, Grankvist K, Kristensen GB, Ibarz M, Panteghini M, Plebani M, Nybo M, Smellie S, Zaninotto M, Simundic AM., European Federation for Clinical Chemistry and Laboratory Medicine Working Group for Preanalytical Phase. Preanalytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working group for Preanalytical Phase (WG-PRE). Clin Chem Lab Med. 2015 Feb;53(3):357-70. [PubMed: 25490032]
- 42.
- Ruppe MD. Medications that affect calcium. Endocr Pract. 2011 Mar-Apr;17 Suppl 1:26-30. [PubMed: 21134875]
- 43.
- Gruber M, Nehring C, Creutzenberg M, Graf B, Hopf S. Perchlorate (Irenat®) may falsely lower measured ionised calcium. Clin Chem Lab Med. 2011 Jun;49(6):1019-24. [PubMed: 21428857]
- 44.
- Liu J, Tio MC, Verma A, Schmidt IM, Ilori TO, Knauf F, Mc Causland FR, Waikar SS. Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease. J Clin Endocrinol Metab. 2022 Jan 01;107(1):e281-e292. [PMC free article: PMC8684460] [PubMed: 34390334]
- 45.
- Manz F, Kehrt R, Lausen B, Merkel A. Urinary calcium excretion in healthy children and adolescents. Pediatr Nephrol. 1999 Nov;13(9):894-9. [PubMed: 10603144]
- 46.
- Jain A, Bhayana S, Vlasschaert M, House A. A formula to predict corrected calcium in haemodialysis patients. Nephrol Dial Transplant. 2008 Sep;23(9):2884-8. [PubMed: 18388119]
- 47.
- Shrimanker I, Bhattarai S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 24, 2023. Electrolytes. [PubMed: 31082167]
- 48.
- Yu E, Sharma S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 14, 2023. Physiology, Calcium. [PubMed: 29489276]
- 49.
- Cano-Torres EA, González-Cantú A, Hinojosa-Garza G, Castilleja-Leal F. Immobilization induced hypercalcemia. Clin Cases Miner Bone Metab. 2016 Jan-Apr;13(1):46-7. [PMC free article: PMC4869954] [PubMed: 27252745]
- 50.
- Bilezikian JP. Hypercalcemia. Dis Mon. 1988 Dec;34(12):737-99. [PubMed: 3061760]
- 51.
- Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015 Jun 02;350:h2723. [PubMed: 26037642]
- 52.
- Turner JJO. Hypercalcaemia - presentation and management . Clin Med (Lond). 2017 Jun;17(3):270-273. [PMC free article: PMC6297576] [PubMed: 28572230]
- 53.
- Farias ML. [Hypercalcemia of malignancy: clinical features, diagnosis and treatment]. Arq Bras Endocrinol Metabol. 2005 Oct;49(5):816-24. [PubMed: 16444366]
- 54.
- Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med. 1981 Autumn;50(200):473-81. [PubMed: 7342172]
- 55.
- Koo WS, Jeon DS, Ahn SJ, Kim YS, Yoon YS, Bang BK. Calcium-free hemodialysis for the management of hypercalcemia. Nephron. 1996;72(3):424-8. [PubMed: 8852491]
- 56.
- Pepe J, Colangelo L, Biamonte F, Sonato C, Danese VC, Cecchetti V, Occhiuto M, Piazzolla V, De Martino V, Ferrone F, Minisola S, Cipriani C. Diagnosis and management of hypocalcemia. Endocrine. 2020 Sep;69(3):485-495. [PubMed: 32367335]
- 57.
- de Brito Galvão JF, Schenck PA, Chew DJ. A Quick Reference on Hypocalcemia. Vet Clin North Am Small Anim Pract. 2017 Mar;47(2):249-256. [PubMed: 28012786]
- 58.
- Garabédian M. [Hypocalcemia]. Rev Prat. 1998 Jun 01;48(11):1201-6. [PubMed: 9781172]
- 59.
- Schenck PA, Chew DJ. Hypocalcemia: a quick reference. Vet Clin North Am Small Anim Pract. 2008 May;38(3):455-8, viii. [PubMed: 18402868]
- 60.
- Bove-Fenderson E, Mannstadt M. Hypocalcemic disorders. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):639-656. [PubMed: 30449546]
- 61.
- Fukumoto S, Namba N, Ozono K, Yamauchi M, Sugimoto T, Michigami T, Tanaka H, Inoue D, Minagawa M, Endo I, Matsumoto T. Causes and differential diagnosis of hypocalcemia--recommendation proposed by expert panel supported by ministry of health, labour and welfare, Japan. Endocr J. 2008 Oct;55(5):787-94. [PubMed: 18490837]
- 62.
- Giancarelli A, Birrer KL, Alban RF, Hobbs BP, Liu-DeRyke X. Hypocalcemia in trauma patients receiving massive transfusion. J Surg Res. 2016 May 01;202(1):182-7. [PubMed: 27083965]
- 63.
- Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract. 2007 Jun;22(3):286-96. [PubMed: 17507729]
- 64.
- Schafer AL, Shoback DM. Hypocalcemia: Diagnosis and Treatment. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): Jan 3, 2016. [PubMed: 25905251]
- 65.
- Boisen IM, Mos I, Lerche-Black EM, Juul A, Bräuner-Osborne H, Blomberg Jensen M. Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1). J Clin Endocrinol Metab. 2020 Apr 01;105(4) [PubMed: 32160303]
- 66.
- Conticini E, Negro A, Magnani L, Ugolini R, Atienza-Mateo B, Frediani B, Salvarani C. Gitelman syndrome associated with chondrocalcinosis and severe neuropathy: a novel heterozygous mutation in SLC12A3 gene. Reumatismo. 2020 Apr 10;72(1):67-70. [PubMed: 32292023]
- 67.
- Hanseree P, Staples AC, Cryns VL, Hansen KE. Hypocalciuria as a Predictor of Reduced Intestinal Calcium Absorption. J Endocr Soc. 2017 Sep 01;1(9):1179-1187. [PMC free article: PMC5686601] [PubMed: 29264573]
- 68.
- Letavernier E, Daudon M. Vitamin D, Hypercalciuria and Kidney Stones. Nutrients. 2018 Mar 17;10(3) [PMC free article: PMC5872784] [PubMed: 29562593]
- 69.
- Wróblewski T, Wystrychowski A. [Hypercalciuria]. Przegl Lek. 2011;68(2):107-13. [PubMed: 21751520]
- 70.
- Alejandro P, Constantinescu F. A Review of Osteoporosis in the Older Adult: An Update. Rheum Dis Clin North Am. 2018 Aug;44(3):437-451. [PubMed: 30001785]
- 71.
- Hauk L., American College of Obstetricians and Gynecologists. ACOG releases practice bulletin on osteoporosis. Am Fam Physician. 2013 Aug 15;88(4):269-75. [PubMed: 23944732]
- 72.
- American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for Prevention of Falls and Their Consequences. J Am Geriatr Soc. 2014 Jan;62(1):147-52. [PubMed: 24350602]
- 73.
- Wallingford JC. Perspective: Structure-Function Claims on Infant Formula. Adv Nutr. 2018 May 01;9(3):183-192. [PMC free article: PMC5952939] [PubMed: 29767697]
- 74.
- Milner JA, McDonald SS, Anderson DE, Greenwald P. Molecular targets for nutrients involved with cancer prevention. Nutr Cancer. 2001;41(1-2):1-16. [PubMed: 12094610]
- 75.
- Terry P, Baron JA, Bergkvist L, Holmberg L, Wolk A. Dietary calcium and vitamin D intake and risk of colorectal cancer: a prospective cohort study in women. Nutr Cancer. 2002;43(1):39-46. [PubMed: 12467133]
- 76.
- Macefield G, Burke D. Paraesthesiae and tetany induced by voluntary hyperventilation. Increased excitability of human cutaneous and motor axons. Brain. 1991 Feb;114 ( Pt 1B):527-40. [PubMed: 2004255]
- 77.
- Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Hölzer S. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer. 2000 Jul 01;89(1):202-17. [PubMed: 10897019]
- 78.
- Glover GH. Multipoint Dixon technique for water and fat proton and susceptibility imaging. J Magn Reson Imaging. 1991 Sep-Oct;1(5):521-30. [PubMed: 1790376]
- 79.
- Guo CJ, Leung PSC, Zhang W, Ma X, Gershwin ME. The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1). Autoimmun Rev. 2018 Jan;17(1):78-85. [PubMed: 29108822]
- 80.
- Chamberlin M, Kemp EH, Weetman AP, Khadka B, Brown EM. Immunosuppressive therapy of autoimmune hypoparathyroidism in a patient with activating autoantibodies against the calcium-sensing receptor. Clin Endocrinol (Oxf). 2019 Jan;90(1):214-221. [PubMed: 30358904]
- 81.
- Rayannavar A, Levitt Katz LE, Crowley TB, Lessig M, Grand K, Goldmuntz E, Zackai EH, McDonald-McGinn DM. Association of hypocalcemia with congenital heart disease in 22q11.2 deletion syndrome. Am J Med Genet A. 2018 Oct;176(10):2099-2103. [PMC free article: PMC6467273] [PubMed: 30277015]
- 82.
- WHO recommendation: Calcium supplementation during pregnancy for the prevention of pre-eclampsia and its complications. World Health Organization; Geneva: 2018. [PubMed: 30629391]
- 83.
- Wilson RL, Phillips JA, Bianco-Miotto T, McAninch D, Goh Z, Anderson PH, Roberts CT. Reduced Dietary Calcium and Vitamin D Results in Preterm Birth and Altered Placental Morphogenesis in Mice During Pregnancy. Reprod Sci. 2020 Jun;27(6):1330-1339. [PubMed: 32046423]
- 84.
- Vuralli D. Clinical Approach to Hypocalcemia in Newborn Period and Infancy: Who Should Be Treated? Int J Pediatr. 2019;2019:4318075. [PMC free article: PMC6607701] [PubMed: 31320908]
- 85.
- Venkataraman PS, Blick KE, Fry HD, Rao RK. Postnatal changes in calcium-regulating hormones in very-low-birth-weight infants. Effect of early neonatal hypocalcemia and intravenous calcium infusion on serum parathyroid hormone and calcitonin homeostasis. Am J Dis Child. 1985 Sep;139(9):913-6. [PubMed: 4036926]
- 86.
- Marques SA, Kakuda AC, Mendaçolli TJ, Abbade LP, Marques ME. Calciphylaxis: a rare but potentially fatal event of chronic kidney disease. Case report. An Bras Dermatol. 2013 Nov-Dec;88(6 Suppl 1):44-7. [PMC free article: PMC3875989] [PubMed: 24346877]
- 87.
- Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci. 1989 Jan;297(1):9-11. [PubMed: 2913801]
- 88.
- Chertow GM, Burke SK, Raggi P., Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002 Jul;62(1):245-52. [PubMed: 12081584]
- 89.
- Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol. 2005 Feb;16(2):507-13. [PubMed: 15601745]
- 90.
- Courbebaisse M, Prot-Bertoye C, Daudon M. [Nephrolithiasis: From mechanisms to preventive medical treatment]. Nephrol Ther. 2020 Feb;16(1):65-75. [PubMed: 32122798]
- 91.
- Sachs C, Rabouine P, Chaneac M, Kindermans C, Dechaux M, Falch-Christiansen T. Preanalytical errors in ionized calcium measurements induced by the use of liquid heparin. Ann Clin Biochem. 1991 Mar;28 ( Pt 2):167-73. [PubMed: 1859155]
- 92.
- Castro-Castro MJ, Candás-Estébanez B, Esteban-Salán M, Calmarza P, Arrobas-Velilla T, Romero-Román C, Pocoví-Mieras M, Aguilar-Doreste JÁ., Commission on Lipoprotein and Vascular Diseases, Sociedad Española de Química Clínica. Removing Lipemia in Serum/Plasma Samples: A Multicenter Study. Ann Lab Med. 2018 Nov;38(6):518-523. [PMC free article: PMC6056396] [PubMed: 30027694]
- 93.
- Fulton II MR, Zubair M, Taghavi S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 27, 2023. Laboratory Evaluation of Sepsis. [PMC free article: PMC594258] [PubMed: 37603649]
- 94.
- Lowe D, Sanvictores T, Zubair M, John S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 29, 2023. Alkaline Phosphatase. [PMC free article: PMC459201] [PubMed: 29083622]
- 95.
- Sonagra AD, Zubair M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 17, 2023. Laboratory Evaluation of Hereditary Hemochromatosis. [PMC free article: PMC594250] [PubMed: 37603641]
- 96.
- Bayat H. Selecting multi-rule quality control procedures based on patient risk. Clin Chem Lab Med. 2017 Oct 26;55(11):1702-1708. [PubMed: 28236626]
- 97.
- Gandhi T, Zubair M, Bhatt H. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 18, 2023. Cancer Antigen 125. [PMC free article: PMC562245] [PubMed: 32965916]
- 98.
- Novack ML, Zubair M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 23, 2023. Natriuretic Peptide B Type Test. [PMC free article: PMC556136] [PubMed: 32310596]
- 99.
- Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001 Jan 15;19(2):558-67. [PubMed: 11208851]
- 100.
- Weaver CM, Peacock M. Calcium. Adv Nutr. 2011 May;2(3):290-2. [PMC free article: PMC3090164] [PubMed: 22332061]
Disclosure: Taylor Drake declares no relevant financial relationships with ineligible companies.
Disclosure: Vikas Gupta declares no relevant financial relationships with ineligible companies.
- [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].[Nefrologia. 2008][Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].Lorenzo Sellares V, Torregrosa V. Nefrologia. 2008; 28 Suppl 3:67-78.
- Hyperphosphatemia.[StatPearls. 2024]Hyperphosphatemia.Rout P, Jialal I. StatPearls. 2024 Jan
- Electrolytes.[StatPearls. 2024]Electrolytes.Shrimanker I, Bhattarai S. StatPearls. 2024 Jan
- Review Pathogenesis of secondary hyperparathyroidism.[Am J Kidney Dis. 1994]Review Pathogenesis of secondary hyperparathyroidism.Slatopolsky E, Delmez JA. Am J Kidney Dis. 1994 Feb; 23(2):229-36.
- Review 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.[Dan Med Bull. 2008]Review 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Brandi L. Dan Med Bull. 2008 Nov; 55(4):186-210.
- Calcium - StatPearlsCalcium - StatPearls
- Pharmacologic Treatment of Overweight and Obesity in Adults - EndotextPharmacologic Treatment of Overweight and Obesity in Adults - Endotext
- TSC22D4 TSC22 domain family member 4 [Homo sapiens]TSC22D4 TSC22 domain family member 4 [Homo sapiens]Gene ID:81628Gene
- 81628[uid] AND (alive[prop]) (1)Gene
- GART phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synt...GART phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase [Homo sapiens]Gene ID:2618Gene
Your browsing activity is empty.
Activity recording is turned off.
See more...